Cenobamate is an investigational antiepileptic drug with a unique dual mechanism of action: it acts via the reduction of persistent currents through voltage-gated sodium channels and positive allosteric modulation of GABAA receptors at the non-benzodiazepine binding site. Cenobamate was approved by the FDA in 2019 and the EMA in 2021 for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients. These approvals followed two major randomized controlled trials which demonstrated that cenobamate significantly reduced median seizure frequency, with more than 20% of patients achieving seizure freedom.

Following its approval, studies have continued to further investigate long-term safety and effectiveness, its performance in defined subpopulations, how it interacts with other anti-epileptic drugs, and how and when best to use it in clinical practice.

In this podcast, William E. Rosenfeld and Pavel Klein share new data from open-label extensions and subgroup analyses, diving deeper into the real-world of cenobamate, as well as sharing practical recommendations for its use in clinical practice.